We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID‐19: A retrospective, cohort study.
- Authors
Hayek, Samah; Ben‐Shlomo, Yatir; Balicer, Ran; Byrne, Katherine; Katz, Mark; Kepten, Eldad; Raz, Itamar; Roitman, Eytan; Zychma, Marcin; Barda, Noam
- Abstract
The outcome of interest was severe COVID-19, defined as a composite outcome of death as a result of COVID-19 or severe COVID-19 illness diagnosed in the 45 days after the initial diagnosis. Models using preinfection HbA1c as a categorical variable prevent a detailed assessment of the dose-response relationship between HbA1c and COVID-19 risk, and furthermore, the use of discrete HbA1c categories may create artificial boundaries between normal and increased risk. Compared with patients who experienced non-severe COVID-19, those with severe COVID-19 had higher preinfection HbA1c (mean [SD] 7.40% [1.60%] vs. 7.21% [1.53%]), were older (mean [SD] 72.9 [12.1] vs. 63.8 [13.0] years), were more probable to be men (56.7% vs. 48.4%) and were significantly more probable to report macrovascular and microvascular diabetes complications. Among 5869 patients with T2D who had a diagnosis of COVID-19, patients with poor glycaemic control were much more probable to have severe outcomes from COVID-19.
- Subjects
COVID-19; GLYCEMIC control; DIABETIC nephropathies; TYPE 2 diabetes; DIABETIC neuropathies; COVID-19 pandemic; PREVENTIVE medicine
- Publication
Diabetes, Obesity & Metabolism, 2021, Vol 23, Issue 8, p1995
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.14393